1. Scrip

Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence

Transforming Big Data Into Meaningful Outcomes For Health

 
• By Eleanor Malone

The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.

Scrip Asks Part 6
• Source: Shutterstock

In the previous installment of Scrip Asks…What Does 2023 Hold For Biopharma?, we asked what technological advance would have the biggest impact on biopharma in 2023. Artificial intelligence was a feature of many responses. In this installment, industry stakeholders share more detail on how they expect AI to change the landscape in 2023.

From understanding protein folding to analyzing pharmaceutical prescribing patterns via improving patient selection for clinical trials, there is no area...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Asks

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.